172 related articles for article (PubMed ID: 23675277)
1. Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.
Markaverich BM; Vijjeswarapu M
Int J Biomed Sci; 2012 Dec; 8(4):219-32. PubMed ID: 23675277
[TBL] [Abstract][Full Text] [Related]
2. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
[TBL] [Abstract][Full Text] [Related]
3. Type II [3H]estradiol binding site antagonists: inhibition of normal and malignant prostate cell growth and proliferation.
Markaverich BM; Alejandro MA
Int J Oncol; 1998 May; 12(5):1127-35. PubMed ID: 9538139
[TBL] [Abstract][Full Text] [Related]
4. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.
Shoulars K; Rodriguez MA; Thompson T; Markaverich BM
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):41-50. PubMed ID: 19837161
[TBL] [Abstract][Full Text] [Related]
5. Bioflavonoids, type II [H-3]estradiol binding sites and prostatic cancer cell proliferation.
Markaverich B; Alejandro M
Int J Oncol; 1997 Dec; 11(6):1311-9. PubMed ID: 21528340
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with a nuclear type-ii site agonist and 5-Fluorouracil - inhibition of mammary-tumor growth.
Markaverich B; Schauweker T; Gregory R; Varma R; Varma M; Kittrell F; Medina D
Int J Oncol; 1993 Mar; 2(3):385-92. PubMed ID: 21573566
[TBL] [Abstract][Full Text] [Related]
7. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones.
Markaverich BM; Schauweker TH; Gregory RR; Varma M; Kittrell FS; Medina D; Varma RS
Cancer Res; 1992 May; 52(9):2482-8. PubMed ID: 1568218
[TBL] [Abstract][Full Text] [Related]
8. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
9. Purification and characterization of nuclear type II [(3)H]estradiol binding sites from the rat uterus: covalent labeling with [(3)H]luteolin.
Markaverich BM; Shoulars K; Brown MA
Steroids; 2001 Sep; 66(9):707-19. PubMed ID: 11546559
[TBL] [Abstract][Full Text] [Related]
10. Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells.
Markaverich BM; Shoulars K; Rodriguez MA
Int J Biomed Sci; 2011; 7(2):101-111. PubMed ID: 21731475
[TBL] [Abstract][Full Text] [Related]
11. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.
Chan QK; Lam HM; Ng CF; Lee AY; Chan ES; Ng HK; Ho SM; Lau KM
Cell Death Differ; 2010 Sep; 17(9):1511-23. PubMed ID: 20203690
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
13. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts.
Markaverich BM; Gregory RR
Steroids; 1993 Jun; 58(6):268-74. PubMed ID: 8212072
[TBL] [Abstract][Full Text] [Related]
14. PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo .
Kubota T; Hisatake J; Hisatake Y; Said JW; Chen SS; Holden S; Taguchi H; Koeffler HP
Prostate; 2000 Feb; 42(3):163-71. PubMed ID: 10639186
[TBL] [Abstract][Full Text] [Related]
15. Luteolin protects PC-12 cells from H
Zhang Z; Xu P; Yu H; Shi L
Biomed Pharmacother; 2019 Apr; 112():108698. PubMed ID: 30802826
[TBL] [Abstract][Full Text] [Related]
16. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
17. A c-fos/Estrogen receptor fusion protein promotes cell cycle progression and proliferation of human cancer cell lines.
Crowe DL; Brown TN; Kim R; Smith SM; Lee MK
Mol Cell Biol Res Commun; 2000 Apr; 3(4):243-8. PubMed ID: 10891399
[TBL] [Abstract][Full Text] [Related]
18. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells.
Lee EJ; Oh SY; Sung MK
Food Chem Toxicol; 2012 Nov; 50(11):4136-43. PubMed ID: 22926442
[TBL] [Abstract][Full Text] [Related]
19. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin.
Chiang CT; Way TD; Lin JK
Mol Cancer Ther; 2007 Jul; 6(7):2127-38. PubMed ID: 17620442
[TBL] [Abstract][Full Text] [Related]
20. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
